Zogenix, Inc. (NASDAQ:ZGNX) Director Roger Hawley sold 35,000 shares of the stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $44.71, for a total value of $1,564,850.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Zogenix, Inc. (NASDAQ ZGNX) opened at $42.05 on Friday. Zogenix, Inc. has a 12-month low of $10.00 and a 12-month high of $45.85. The stock has a market capitalization of $1,524.24, a price-to-earnings ratio of -9.06 and a beta of 1.57.
Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings data on Tuesday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.17). Zogenix had a negative return on equity of 81.65% and a negative net margin of 309.76%. During the same period in the previous year, the firm earned ($0.95) EPS. equities analysts anticipate that Zogenix, Inc. will post -3.12 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new stake in shares of Zogenix during the 3rd quarter worth $226,000. Sterling Capital Management LLC purchased a new stake in shares of Zogenix during the 3rd quarter worth $237,000. Teacher Retirement System of Texas purchased a new stake in shares of Zogenix during the 4th quarter worth $409,000. Raymond James & Associates purchased a new stake in shares of Zogenix during the 4th quarter worth $460,000. Finally, Guggenheim Capital LLC lifted its stake in shares of Zogenix by 71.2% during the 4th quarter. Guggenheim Capital LLC now owns 12,843 shares of the company’s stock worth $514,000 after purchasing an additional 5,342 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “Zogenix, Inc. (ZGNX) Director Sells $1,564,850.00 in Stock” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2018/03/17/zogenix-inc-zgnx-director-sells-1564850-00-in-stock.html.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.